Mesoblast (OTC: MEOBF) outlines ASX new equity and director updates

Rhea-AI Filing Summary

Mesoblast Limited, an Australia-based biotechnology company, submitted a report outlining several equity-related actions first lodged with the Australian Securities Exchange on January 13, 2026. The company attached three ASX appendices to this report for investors’ reference.

One appendix covers a new issue announcement and notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G). A second appendix details a new issue announcement and application for quotation of securities (Appendix 2A). A third appendix reports a new issue announcement and change of a director’s interest (Appendix 3Y). Together, these documents describe recent equity issuances and an update to director holdings, with the full details contained in the attached exhibits.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On January 13, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On January 13, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, application for quotation of securities (Appendix 2A) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

On January 13, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.3, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: January 14, 2026

INDEX TO EXHIBITS

Item
99.1						Appendix 3G of Mesoblast Ltd, dated January 13, 2026.
99.2						Appendix 2A of Mesoblast Ltd, dated January 13, 2026.
99.3						Appendix 3Y of Mesoblast Ltd, dated January 13, 2026.

FAQ

What does Mesoblast Limited (MEOBF) report in this Form 6-K?

The report states that Mesoblast Limited has provided three Australian Securities Exchange appendices describing a new issue of unquoted equity securities, an application for quotation of securities, and a change in a director’s interest. These documents are attached as exhibits for more detail.

Which ASX documents are attached to Mesoblast Limited’s (MEOBF) January 2026 report?

The report attaches Appendix 3G (new issue announcement for unquoted equity securities), Appendix 2A (new issue announcement and application for quotation of securities), and Appendix 3Y (new issue announcement and change of director’s interest notice), each dated January 13, 2026.

What type of securities activity does Mesoblast (MEOBF) reference in this report?

The report references a new issue of unquoted equity securities, an application for quotation of securities on the Australian Securities Exchange, and an associated change in a director’s equity interest, as described in the attached appendices.

How are the ASX appendices incorporated for Mesoblast Limited (MEOBF)?

Each of the three ASX appendices—Appendix 3G, Appendix 2A, and Appendix 3Y—is attached to the report as an exhibit and expressly incorporated by reference, meaning their contents form part of the overall disclosure.

Who is identified as a key executive in Mesoblast Limited’s (MEOBF) report?

The report identifies Silviu Itescu as Chief Executive Officer and Executive Director and lists the company’s principal executive offices in Melbourne, Australia. It also shows that the report was signed by Company Secretary Niva Sivakumar.